XBIO Research and Charts

XBIO - Xenetic Biosciences Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-01-03)

Last 4.25	Change ⇑ +0.20 (+4.94%)	Volume 13,686
	Open 4.03	High 4.32	Low 4.03

8EMA (Daily) 4.12	40EMA (Daily) 4.10	50EMA (Daily) 4.09	STO (Daily) 41.680	MACD Hist (Daily) -0.018
8EMA (Weekly) 4.150	40EMA (Weekly) 3.96	50EMA (Weekly) 3.88	STO (Weekly) 43.399	MACD Hist (Weekly) 0.043


Company Profile
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.